Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement to acquire Lowell will also include LTX-608, Lowell's proprietary nafamostat formulation for direct IV infusion being developed for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).
Lead Product(s): Nafamostat
Therapeutic Area: Hematology Product Name: LTX-608
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AcelRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 15, 2021